Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

IMPORTANCE: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Shitara, Kohei, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez, Karaseva, Nina, Caglevic, Christian, Villanueva, Luis, Goekkurt, Eray, Satake, Hironaga, Enzinger, Peter, Alsina, Maria, Benson, Al, Chao, Joseph, Ko, Andrew H., Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, S. Peter, Tabernero, Josep
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489405/
https://ncbi.nlm.nih.gov/pubmed/32880601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3370
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky